KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Profit After Tax (2016 - 2025)

Vertex Pharmaceuticals has reported Profit After Tax over the past 17 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Profit After Tax at $1.2 billion for Q4 2025, up 30.46% from a year ago — trailing twelve months through Dec 2025 was $4.0 billion (up 838.09% YoY), and the annual figure for FY2025 was $4.0 billion, up 838.09%.
  • Profit After Tax for Q4 2025 was $1.2 billion at Vertex Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over the last five years, Profit After Tax for VRTX hit a ceiling of $1.2 billion in Q4 2025 and a floor of -$3.6 billion in Q2 2024.
  • Median Profit After Tax over the past 5 years was $882.4 million (2021), compared with a mean of $635.1 million.
  • Biggest five-year swings in Profit After Tax: soared 1109.7% in 2022 and later plummeted 492.44% in 2024.
  • Vertex Pharmaceuticals' Profit After Tax stood at $770.1 million in 2021, then grew by 6.34% to $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then fell by 5.76% to $913.0 million in 2024, then surged by 30.46% to $1.2 billion in 2025.
  • The last three reported values for Profit After Tax were $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.